Does Masteron Lower Estrogen? What Your Bloodwork Actually Shows

You added Masteron to your cycle because everyone said it keeps estrogen in check. Maybe you even dropped your AI. Six weeks later your knees ache, your estradiol came back higher than you expected, and the forum thread you asked in has split into two camps shouting at each other.

Both camps are half right, and the reason is the most useful thing to understand about this compound. Masteron changes how estrogen behaves in your body far more reliably than it changes the number on your lab report. Here is what the evidence supports, where it runs out, and how to read your own bloodwork on a test and Masteron cycle.

Does Masteron lower estrogen?

Start with the chemistry, because it settles half the argument. Drostanolone is 2α-methyl-dihydrotestosterone: DHT with a methyl group bolted on. DHT is already 5α-reduced, which means it has lost the double bond that aromatase needs to build an estrogen ring. Researchers who run DHT trials describe it plainly as "neither aromatizable nor susceptible to potency amplification by 5α reduction" (Ly et al., 2001). Drostanolone shares that structure, so it is not expected to become estrogen.

So Masteron does not add estrogen. The forum claim goes further, though. It says Masteron acts like an AI and actively pulls E2 down. Here the evidence gets thin fast:

• No study has tested drostanolone against aromatase. Not in a test tube, not in a human. A PubMed search for drostanolone and aromatase returns nothing on the question.
• The closest data is weak and indirect. In rat ovarian cells, DHT and a related 5α-reduced steroid competitively inhibited aromatase (Hillier et al., 1980). In human ovarian cells, DHT only suppressed aromatase at micromolar concentrations, and actually stimulated it at lower ones (Kirilovas et al., 2003). Serum DHT in men sits in the nanomolar range, roughly a thousand times lower.
• Its cancer history does not prove an AI effect. Drostanolone propionate (sold as Masteril and Drolban) was used for advanced breast cancer in the 1960s and 70s. In a controlled comparison it performed about the same as nandrolone and testolactone, with remission rates averaging 24% at four weeks (Wolff and Rieche, 1978). A drug that shrinks estrogen-sensitive tumours can do so through the androgen receptor without touching serum E2.

When users run bloodwork, their reports match this. Experienced members on every forum we read say the same thing: Masteron "won't lower your E2 in bloods."

So why does E2 sometimes drop on test and Masteron?

Because of what else changes when you add it. Most men who add Masteron either lower their testosterone dose to make room for it, or were going to shut down their own production anyway. Both reduce the raw material aromatase works on.

The cleanest data on this comes from a 2013 NEJM trial that shut down 198 healthy men's own hormones and then gave them fixed doses of testosterone gel (Finkelstein et al., 2013). Estradiol, measured by mass spectrometry, rose in step with testosterone:

A graded-dose study in 103 men took this into cycle territory, 25 to 600 mg of testosterone enanthate a week, and found total and free E2 rose with dose, with conversion slowing (saturating) at the top end (Lakshman et al., 2010). Your E2 follows your test dose. Masteron is not an input to that equation, except when you drop test to make room for it.

The DHT gel trials show the other half. Giving older men DHT, a non-aromatizable androgen, suppressed their LH and their own testosterone, and E2 fell with it in two of three trials (Kunelius et al., 2002; Idan et al., 2010). In the third, E2 did not change (Ly et al., 2001). That is suppression, not aromatase inhibition, and it only matters if something else is not already supplying the testosterone.

Masked high E2 versus real low E2

If Masteron does not reliably lower E2, why do so many people swear it controls their estrogen side effects? The likely explanation is that androgens push back against estrogen at the tissue level.

In female monkeys, estradiol alone raised breast tissue cell division about six-fold. Adding testosterone cut that estrogen-driven proliferation by around 40% and wiped out the rise in estrogen receptor expression (Zhou et al., 2000). If a strong androgen does something similar in male breast tissue, it would explain why men on Masteron report fewer nipple symptoms and less "estrogenic" puffiness at the same serum E2.

Two caveats. Nobody has tested this in men on drostanolone. And androgen and estrogen crosstalk is not simple: in some estrogen-positive breast cancers the androgen receptor actually helps estrogen signalling (D'Amato et al., 2016). "Masks symptoms" is a reasonable working model, not a proven mechanism.

This model makes a practical prediction, and it is the one that catches people out.

What if I feel low E2 but my estradiol is normal?

Sore or dry joints, flat libido, low mood and anxiety are the classic low-E2 complaints, and they are the most common Masteron complaints on every forum we read. Often the bloodwork shows E2 in range.

There are three explanations worth separating:

1. Tissue effect without a serum change. If Masteron is blunting estrogen action in tissue, you can feel the effects of less estrogen with a normal number. This is the "masking" model working in the direction nobody wanted.
2. Your lab test is flattering you. Standard immunoassays read E2 high in men. Five commercial immunoassays over-read by between 6% and 74% compared with mass spectrometry (Handelsman et al., 2014). In 3,174 European men, a platform immunoassay caught genuinely low E2 only 13.3% of the time (Huhtaniemi et al., 2012). A "normal" standard result on Masteron plus an AI can hide a real crash.
3. Something else entirely. Joint pain has plenty of causes, and the link between low estrogen and joint pain is established in women on AIs, not in men. Do not assume.

The step that separates these is a sensitive (LC-MS/MS) estradiol test. If it comes back genuinely low, you have a real E2 problem, usually from an AI or too little testosterone. If it comes back normal, lower the Masteron dose before touching anything else and see whether the symptoms follow.

Does low E2 actually kill libido if androgens are high?

Less than forums assume, at least in healthy men. When 114 men over 50 used DHT gel for two years, their E2 was fully suppressed, yet none of 33 sexual function and mood measures changed apart from a mild decrease in overall desire, which reversed after treatment stopped (Sartorius et al., 2014).

Estrogen still matters, though. In the Finkelstein trial, men with testosterone in the 200 to 400 ng/dL range lost 13% of their sexual desire score if E2 stayed at or above 10 pg/mL, and 31% if it fell below. On a cycle, testosterone is far higher than that, which likely buffers you. The forum pattern fits: libido tends to hold when test clearly outweighs Masteron, and drops when men run Masteron above their test dose. If yours has crashed, our TRT libido troubleshooting guide walks through the other causes first.

SHBG and free testosterone on Masteron

This is the effect Masteron almost certainly does have, and it changes how you should read your testosterone results.

SHBG is the protein that carries testosterone in your blood. Androgens tell the liver to make less of it. In power athletes self-administering steroids for 26 weeks, SHBG fell by 80 to 90% and stayed low for 16 weeks after they stopped (Ruokonen et al., 1985). The drop runs through the androgen receptor and happens within days (Sinnecker and Köhler, 1989).

5α-reduced androgens also bind SHBG more tightly than testosterone does. DHT outranks testosterone, and mesterolone (Proviron, a 1α-methyl DHT) binds about four times more tightly than DHT itself (Saartok et al., 1984). Drostanolone was not in that study, so its exact binding is unmeasured, but the direction is plausible.

What that means on your lab report:

• Total testosterone can look lower than your real exposure, because there is less SHBG carrying it.
• Free testosterone becomes the number to watch. Calculated free T using the Vermeulen equation matched the gold-standard method in every condition studied except pregnancy, while direct "analog" free T immunoassays gave only a fraction of the true value (Vermeulen et al., 1999). Use calculated free T, not the direct assay.
• Some labs will refuse to calculate it. One forum member's lab would not report free T once SHBG hit 8 nmol/L. If your SHBG is below the lab's range, ask them to run it anyway or calculate it yourself from total T, SHBG and albumin.

Does 300 mg of Masteron make test act like 600 mg?

No study supports this. The kernel of truth is that lower SHBG leaves more testosterone free, so a given total testosterone can do more. Nobody has measured how much for drostanolone, and it is not a doubling. The strongest documented SHBG suppressors are oral 17α-alkylated compounds like stanozolol, not injectables. If your stack includes an oral, that is probably what flattened your SHBG.

Test to Masteron ratio: set it from your numbers

Forum ratios range from 2:1 (twice as much test as Masteron) to 1:1, with a near-universal rule that Masteron should not exceed the testosterone dose. There is no clinical data behind any of them. The only dose-response human data for drostanolone come from 1970s breast cancer trials in women (Talley et al., 1973).

Given that E2 follows test and not Masteron, the useful question is not "what ratio" but "what do my numbers say". Use this as a starting framework, not a prescription:

What users report on the forums (anecdotal)

We read Masteron threads on Evolutionary.org, EliteFitness and UGL Talk to see what men running it actually describe. This is anecdotal evidence: self-reports, unverified doses and products of unknown purity. It is useful for spotting patterns and bad for proving anything. Here is what came up again and again, set against what the research supports.

• "It works like an AI" versus "it won't touch your E2." Newer members tend to believe the first. Experienced members, including one who had checked with LC-MS/MS testing, overwhelmingly say the second. The research sides with the veterans.
• Sore, dry joints. The single most common complaint on all three forums. Several men fixed it by cutting their Masteron dose, not by adding estrogen. That fits the tissue-masking model better than a serum E2 drop.
• Libido depends on the ratio. One user described losing libido on 200 mg test with 500 mg Masteron, and keeping it when he ran twice as much test as Masteron. Others report a clear libido boost at test-heavy ratios.
• Hair loss is the main reason people quit. Reports range from mild shedding to "lost half my hair", with a minority who notice nothing. Scalp bumps, rashes and acne come up too.
• "You'll crush your SHBG." Widely assumed, and it matches the research direction.
• The fake-vial pattern. Several Australian users added "Masteron" and watched both total testosterone and E2 jump well above their TRT baseline. The product turned out to be testosterone or nandrolone. Masteron has been hard to source in Australia, which makes substitution more likely.

That last one is the most useful thing the forums taught us. Real Masteron cannot raise your E2. If E2 and total testosterone both climb sharply after you add it, and your test dose did not change, suspect the vial before you suspect your body. Our guide to testing UGL steroids covers how people verify what they are injecting.

What Masteron does to haematocrit, lipids and PSA

Most Masteron guides skip this section because it has nothing to do with estrogen. It matters anyway.

Haematocrit: non-aromatizing does not mean haematocrit-neutral

Red blood cell production is driven through the androgen receptor, not through estrogen. In two aromatase-deficient men who could not make estrogen at all, high-dose testosterone still raised haemoglobin and haematocrit (Rochira et al., 2009). Blocking testosterone's conversion to DHT with dutasteride did not change the haematocrit rise either (Bhasin et al., 2012). Any androgen receptor agonist can do it.

DHT itself, the parent of Masteron, clearly does:

• Six months of DHT gel raised haematocrit from 43.5% to 45.8% (Kunelius et al., 2002).
• Two years of DHT gel raised haemoglobin 7%, and 8 men in the DHT group (of 114 randomised) had to stop because of high haematocrit (Idan et al., 2010).

Those were gel doses in older men. Injected Masteron on top of a testosterone base is a larger androgen load, so treat those numbers as a floor. There is no drostanolone-specific haematocrit data. Watch haematocrit and haemoglobin at 6 to 8 weeks, and treat 54% as your upper limit. That is the Endocrine Society's threshold to stop testosterone therapy (Bhasin et al., 2018); it was written for TRT in hypogonadal men, not for cycles, so it is a borrowed line, not a safe target. Our guide to lowering haematocrit on TRT covers what to do if it climbs.

Lipids: probably lower HDL, never measured alone

Androgens lower HDL by switching on hepatic lipase, the liver enzyme that breaks HDL down. Three weeks of 600 mg testosterone a week raised hepatic lipase activity by more than 60% (Herbst et al., 2003).

Aromatization may cushion this. When men took 280 mg a week of testosterone enanthate, HDL did not fall. When they took the same dose with an aromatase inhibitor, HDL fell from 1.18 to 0.89 mmol/L, and on a non-aromatizing oral androgen it fell from 1.20 to 0.77 mmol/L (Friedl et al., 1990). A newer study found estradiol did not move lipids in testosterone-clamped men (Roelfsema et al., 2018), so the estrogen cushion is disputed.

In real multi-compound cycles, HDL fell from 1.08 to 0.43 mmol/L and had not recovered six weeks after stopping (Hartgens et al., 2004). No study has measured Masteron's lipid effect on its own. Being injectable and not 17α-alkylated, it is likely milder than orals like Winstrol, but that is an expectation. Track HDL, LDL and ApoB, and see our cholesterol on steroids guide for where Masteron sits against other compounds.

PSA and the prostate

Two years of DHT gel did not change prostate volume or PSA compared with placebo, and none of the three men who stopped for PSA rises had cancer (Idan et al., 2010). The authors are clear that their study cannot rule out effects on cancer, and it used healthy men on modest doses. If you are over 40, get a baseline PSA before adding Masteron and recheck it.

Hair loss: why finasteride probably will not save you

Finasteride and dutasteride work by blocking the conversion of testosterone to DHT, and that conversion drives male pattern hair loss (Olsen et al., 2006). Masteron is already a DHT derivative. It does not need converting, so a 5α-reductase inhibitor has nothing to block. No study has tested this directly, but the mechanism is straightforward. If you are prone to hair loss, Masteron is one of the riskiest compounds you can add. Our TRT hair loss and DHT guide covers the options that do work on the scalp.

Masteron propionate vs enanthate: when to test

Masteron comes in two esters. Propionate is short and is typically injected every other day. Enanthate is longer and usually injected once or twice a week. There is no published human pharmacokinetic data for either drostanolone ester, so all timing advice is borrowed from the equivalent testosterone esters and should be treated as an estimate.

• Wait for steady state. Levels settle after roughly four to five half-lives. As a rough guide, that is under a week for propionate and three to four weeks or more for enanthate. Testing before then shows you a moving target.
• Draw at trough. Take blood just before your next injection. A draw the morning after a propionate injection catches the peak and exaggerates everything.
• Note the timing on every result. Write down the date and time of your last injection so you can compare like with like. Our blood test timing guide goes into this.
• Clearance is slow. In anti-doping studies, the main drostanolone metabolite was detectable in urine for up to 29 days (Albertsdóttir et al., 2020). That is detection, not half-life, but it tells you effects on SHBG and lipids will not reverse the week you stop.

The Masteron bloodwork panel

Never run Masteron without a testosterone base. On its own it shuts down your own testosterone and supplies no estrogen, which is a reliable way to end up with genuinely crashed E2.

Frequently asked questions

Does Masteron cause gyno?

Masteron cannot convert to estrogen, and androgens appear to oppose estrogen in breast tissue, so it is unlikely to cause gyno by itself. It will not stop gyno driven by a high test dose if that dose is aromatizing heavily, and a fake "Masteron" vial containing testosterone or nandrolone can. If nipple symptoms appear after adding Masteron, check E2 and total T.

Can I use Masteron instead of an AI?

Not as a like-for-like swap. Masteron may reduce how much estrogen side effects bother you, but it does not reliably lower serum E2. If your E2 is causing real symptoms, lowering your test dose is the more predictable lever. Compare that with EQ, which does suppress E2 through its metabolite; our EQ and estrogen guide explains the difference.

Can I add Masteron to TRT?

People do, commonly at low doses on a cruise. Everything above still applies: SHBG will likely drop, haematocrit and HDL need watching, hair risk is real, and your TRT dose stays the main driver of E2. Get bloodwork before and 4 to 6 weeks after.

Does Masteron increase haematocrit?

Almost certainly, to some degree. Every androgen that activates the androgen receptor can raise red cell production, and DHT, its parent compound, clearly does. No study has measured drostanolone specifically.

Key takeaways

• Masteron is a DHT derivative. It cannot become estrogen, but there is no human evidence it blocks aromatase or lowers serum E2
• Your E2 on test and Masteron tracks your testosterone dose. Lowering test is the lever that moves E2
• Masteron likely blunts estrogen's effects in tissue, which can hide high-E2 symptoms and cause low-E2 symptoms with normal bloodwork
• Use a sensitive LC-MS/MS estradiol test. Standard immunoassays over-read E2 in men, and a common platform immunoassay missed most genuinely low results in one large study
• Expect SHBG to fall. Read calculated free T, not total T
• Non-aromatizing does not mean haematocrit-neutral. Watch haematocrit and HDL as you would on any androgen
• If E2 and total T both jump after adding Masteron, suspect the vial
• Finasteride is unlikely to protect your hair from Masteron

---

References

1. Albertsdóttir, A. D., Van Gansbeke, W., Coppieters, G., Balgimbekova, K., Van Eenoo, P., & Polet, M. (2020). Searching for new long-term urinary metabolites of metenolone and drostanolone using gas chromatography-mass spectrometry with a focus on non-hydrolysed sulfates. Drug Testing and Analysis, 12(8), 1041-1053. PubMed

2. Bhasin, S., Brito, J. P., Cunningham, G. R., et al. (2018). Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism, 103(5), 1715-1744. PubMed

3. Bhasin, S., Travison, T. G., Storer, T. W., et al. (2012). Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production. JAMA, 307(9), 931-939. PubMed

4. D'Amato, N. C., et al. (2016). Cooperative dynamics of AR and ER activity in breast cancer. Molecular Cancer Research, 14(11), 1054-1067. PubMed

5. Finkelstein, J. S., Lee, H., Burnett-Bowie, S. A., et al. (2013). Gonadal steroids and body composition, strength, and sexual function in men. New England Journal of Medicine, 369(11), 1011-1022. PubMed

6. Friedl, K. E., Hannan, C. J., Jones, R. E., & Plymate, S. R. (1990). High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism, 39(1), 69-74. PubMed

7. Handelsman, D. J., Newman, J. D., Jimenez, M., McLachlan, R., Sartorius, G., & Jones, G. R. (2014). Performance of direct estradiol immunoassays with human male serum samples. Clinical Chemistry, 60(3), 510-517. PubMed

8. Hartgens, F., Rietjens, G., Keizer, H. A., Kuipers, H., & Wolffenbuttel, B. H. (2004). Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). British Journal of Sports Medicine, 38(3), 253-259. PubMed

9. Herbst, K. L., Amory, J. K., Brunzell, J. D., Chansky, H. A., & Bremner, W. J. (2003). Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk. American Journal of Physiology: Endocrinology and Metabolism, 284(6), E1112-E1118. PubMed

10. Hillier, S. G., van den Boogaard, A. M., Reichert, L. E., & van Hall, E. V. (1980). Alterations in granulosa cell aromatase activity accompanying preovulatory follicular development in the rat ovary with evidence that 5α-reduced C19 steroids inhibit the aromatase reaction in vitro. Journal of Endocrinology, 84(3), 409-419. PubMed

11. Huhtaniemi, I. T., Tajar, A., Lee, D. M., et al. (2012). Comparison of serum testosterone and estradiol measurements in 3174 European men using platform immunoassay and mass spectrometry. European Journal of Endocrinology, 166(6), 983-991. PubMed

12. Idan, A., Griffiths, K. A., Harwood, D. T., et al. (2010). Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. Annals of Internal Medicine, 153(10), 621-632. PubMed

13. Kirilovas, D., et al. (2003). Effects of androgens on aromatase activity and 11C-vorozole binding in granulosa cells in vitro. Acta Obstetricia et Gynecologica Scandinavica, 82(3), 209-215. PubMed

14. Kunelius, P., Lukkarinen, O., Hannuksela, M. L., Itkonen, O., & Tapanainen, J. S. (2002). The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. Journal of Clinical Endocrinology and Metabolism, 87(4), 1467-1472. PubMed

15. Lakshman, K. M., Kaplan, B., Travison, T. G., et al. (2010). The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. Journal of Clinical Endocrinology and Metabolism, 95(8), 3955-3964. PubMed

16. Ly, L. P., Jimenez, M., Zhuang, T. N., Celermajer, D. S., Conway, A. J., & Handelsman, D. J. (2001). A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. Journal of Clinical Endocrinology and Metabolism, 86(9), 4078-4088. PubMed

17. Olsen, E. A., Hordinsky, M., Whiting, D., et al. (2006). The importance of dual 5α-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. Journal of the American Academy of Dermatology, 55(6), 1014-1023. PubMed

18. Rochira, V., Zirilli, L., Madeo, B., Maffei, L., & Carani, C. (2009). Testosterone action on erythropoiesis does not require its aromatization to estrogen: insights from the testosterone and estrogen treatment of two aromatase-deficient men. Journal of Steroid Biochemistry and Molecular Biology, 113(3-5), 189-194. PubMed

19. Roelfsema, F., Yang, R. J., & Veldhuis, J. D. (2018). Estradiol does not influence lipid measures and inflammatory markers in testosterone-clamped healthy men. Journal of the Endocrine Society, 2(8), 882-892. PubMed

20. Ruokonen, A., Alén, M., Bolton, N., & Vihko, R. (1985). Response of serum testosterone and its precursor steroids, SHBG and CBG to anabolic steroid and testosterone self-administration in man. Journal of Steroid Biochemistry, 23(1), 33-38. PubMed

21. Saartok, T., Dahlberg, E., & Gustafsson, J. A. (1984). Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology, 114(6), 2100-2106. PubMed

22. Sartorius, G. A., Ly, L. P., & Handelsman, D. J. (2014). Male sexual function can be maintained without aromatization: randomized placebo-controlled trial of dihydrotestosterone (DHT) in healthy, older men for 24 months. Journal of Sexual Medicine, 11(10), 2562-2570. PubMed

23. Sinnecker, G., & Köhler, S. (1989). Sex hormone-binding globulin response to the anabolic steroid stanozolol: evidence for its suitability as a biological androgen sensitivity test. Journal of Clinical Endocrinology and Metabolism, 68(6), 1195-1200. PubMed

24. Talley, R. W., Haines, C. R., Waters, M. N., Goldenberg, I. S., Olson, K. B., & Bisel, H. F. (1973). A dose-response evaluation of androgens in the treatment of metastatic breast cancer. Cancer, 32(2), 315-320. PubMed

25. Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999). A critical evaluation of simple methods for the estimation of free testosterone in serum. Journal of Clinical Endocrinology and Metabolism, 84(10), 3666-3672. PubMed

26. Wolff, G., & Rieche, K. (1978). Androgen therapy of incurable breast neoplasms. Controlled clinical study: nandrolone, testololactone, drostanolone. Onkologie, 1(4), 172-174. PubMed

27. Zhou, J., Ng, S., Adesanya-Famuiya, O., Anderson, K., & Bondy, C. A. (2000). Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB Journal, 14(12), 1725-1730. PubMed